Equillium Inc Net Assets
Equillium Inc net assets. Based on the latest financial reports, Equillium Inc (EQ) has net assets worth $56.02 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($58.67 Million) and total liabilities ($2.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Equillium Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $56.02 Million |
| % of Total Assets | 95.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | -57.0% |
| 10-Year Change | N/A |
| Growth Volatility | 41.43 |
Net Assets of Equillium Inc (2017–2025)
Net assets of Equillium Inc from 2017 to 2025. This chart illustrates how Equillium Inc's net assets have evolved over time, based on quarterly financial data. See how leveraged is Equillium Inc's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Equillium Inc (2017–2025)
The table below shows the annual net assets of Equillium Inc from 2017 to 2025. For live market cap and overall valuation, see EQ market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $28.60 Million | +50.03% |
| 2024-12-31 | $19.06 Million | -15.56% |
| 2023-12-31 | $22.57 Million | -29.33% |
| 2022-12-31 | $31.94 Million | -51.97% |
| 2021-12-31 | $66.50 Million | -4.79% |
| 2020-12-31 | $69.85 Million | +66.92% |
| 2019-12-31 | $41.85 Million | -35.55% |
| 2018-12-31 | $64.94 Million | +2983.33% |
| 2017-12-31 | $-2.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Equillium Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21394312600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Equillium Inc Net Assets Breakdown (December 2025)
Equillium Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.02% |
| Other Comprehensive Income | $363.00K | 1.27% |
| Other Components | $244.43 Million | 854.75% |
| Total Equity | $28.60 Million | 100.00% |
Equillium Inc Competitors by Market Cap
The table below lists competitors of Equillium Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Dongzhu Landscape Co
SHG:603359
|
$89.43 Million |
|
Agrify Corp
NASDAQ:AGFY
|
$89.44 Million |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
$89.46 Million |
|
Leofoo Development Co Ltd
TW:2705
|
$89.51 Million |
|
Loop Telecommunication International Inc
TW:3025
|
$89.38 Million |
|
OPPSTAR
KLSE:0275
|
$89.37 Million |
|
Leadtrend Technology Corp
TW:3588
|
$89.36 Million |
|
Country Group Holdings Public Company Limited
BK:CGH
|
$89.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Equillium Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,061,000 to 28,597,000, a change of 9,536,000 (50.0%).
- Net loss of 22,398,000 reduced equity.
- New share issuances of 682,000 increased equity.
- Other comprehensive income decreased equity by 418,000.
- Other factors increased equity by 31,670,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.40 Million | -78.32% |
| Share Issuances | $682.00K | +2.38% |
| Other Comprehensive Income | $-418.00K | -1.46% |
| Other Changes | $31.67 Million | +110.75% |
| Total Change | $- | 50.03% |
Book Value vs Market Value Analysis
This analysis compares Equillium Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.13 | $1.41 | x |
| 2018-12-31 | $5.33 | $1.41 | x |
| 2019-12-31 | $2.41 | $1.41 | x |
| 2020-12-31 | $3.43 | $1.41 | x |
| 2021-12-31 | $2.31 | $1.41 | x |
| 2022-12-31 | $0.95 | $1.41 | x |
| 2023-12-31 | $0.65 | $1.41 | x |
| 2024-12-31 | $0.54 | $1.41 | x |
| 2025-12-31 | $0.31 | $1.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Equillium Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -78.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17229.23%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-78.32%) is below the historical average (-61.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.04 Million |
| 2018 | -20.41% | 0.00% | 0.00x | 1.03x | $-19.74 Million |
| 2019 | -61.12% | 0.00% | 0.00x | 1.33x | $-29.76 Million |
| 2020 | -42.61% | 0.00% | 0.00x | 1.22x | $-36.75 Million |
| 2021 | -58.61% | 0.00% | 0.00x | 1.28x | $-45.63 Million |
| 2022 | -195.44% | -396.14% | 0.20x | 2.46x | $-65.62 Million |
| 2023 | -59.08% | -36.96% | 0.71x | 2.24x | $-15.59 Million |
| 2024 | -42.32% | -19.63% | 1.61x | 1.34x | $-9.97 Million |
| 2025 | -78.32% | -17229.23% | 0.00x | 1.12x | $-25.26 Million |
Industry Comparison
This section compares Equillium Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Equillium Inc (EQ) | $56.02 Million | 0.00% | 0.05x | $89.41 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 fo… Read more